Seasonal trivalent influenza vaccine, Fluarix — Competitive Intelligence Brief

Seasonal trivalent influenza vaccine, Fluarix (Seasonal trivalent influenza vaccine, Fluarix) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: inactivated influenza vaccine. Area: Immunology.

marketed inactivated influenza vaccine Immunology Biologic

Target snapshot

Seasonal trivalent influenza vaccine, Fluarix (Seasonal trivalent influenza vaccine, Fluarix) — Center for Disease Prevention and Control of Beijing Military Region. Fluarix is an inactivated influenza vaccine that stimulates the immune system to produce antibodies against three seasonal influenza virus strains.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Seasonal trivalent influenza vaccine, Fluarix TARGET	Seasonal trivalent influenza vaccine, Fluarix	Center for Disease Prevention and Control of Beijing Military Region	marketed	inactivated influenza vaccine
Fluzone® (IM)	Fluzone® (IM)	National Institute of Allergy and Infectious Diseases (NIAID)	marketed	inactivated influenza vaccine
Standard IIV4	Standard IIV4	Marshfield Clinic Research Foundation	marketed	Inactivated influenza vaccine
Pandemic influenza A/H1N1 vaccine	Pandemic influenza A/H1N1 vaccine	Sinovac Biotech Co., Ltd	marketed	inactivated influenza vaccine
Influsplit SSW® 2005/2006	Influsplit SSW® 2005/2006	GlaxoSmithKline	marketed	Inactivated influenza vaccine
HD-TIV	HD-TIV	McGill University Health Centre/Research Institute of the McGill University Health Centre	marketed	Inactivated influenza vaccine
Seasonal trivalent vaccine	Seasonal trivalent vaccine	Sinovac Biotech Co., Ltd	marketed	Inactivated influenza vaccine

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (inactivated influenza vaccine class)

1. Seqirus · 3 drugs in this class
2. Center for Disease Prevention and Control of Beijing Military Region · 2 drugs in this class
3. Sanofi Pasteur, a Sanofi Company · 2 drugs in this class
4. Sinovac Biotech Co., Ltd · 2 drugs in this class
5. La Jolla Institute for Immunology · 1 drug in this class
6. Mount Sinai Hospital, Canada · 1 drug in this class
7. National Institute of Allergy and Infectious Diseases (NIAID) · 1 drug in this class
8. University of Sao Paulo · 1 drug in this class
9. GlaxoSmithKline · 1 drug in this class
10. University of Witwatersrand, South Africa · 1 drug in this class